Source link : https://www.newshealth.biz/health-news/novel-drug-shows-benefits-in-rare-c3g-and-primary-ic-mpgn/
SAN DIEGO — The investigational drug pegcetacoplan, a C3/C3b inhibitor, showed significant benefits in the treatment of patients with C3 glomerulopathy or primary immune complex–mediated membranoproliferative glomerulonephritis (IC-MPGN) in the largest trial of its kind of these rare and debilitating kidney diseases. For the primary endpoint of a change in proteinuria from baseline, as measured […]
Author : News Health
Publish date : 2024-10-29 08:12:37
Copyright for syndicated content belongs to the linked Source.